Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis

Maria Rehnberg, Sylvie Amu, Andrej Tarkowski, Maria I Bokarewa, Mikael Brisslert, Maria Rehnberg, Sylvie Amu, Andrej Tarkowski, Maria I Bokarewa, Mikael Brisslert

Abstract

Introduction: In the present study we evaluated changes in the B cell phenotype in peripheral blood and bone marrow (BM) of patients with rheumatoid arthritis (RA) following anti-CD20 treatment using rituximab.

Methods: Blood and BM samples were obtained from 37 patients with RA prior to rituximab treatment. Ten of these patients were resampled 1 month following rituximab, 14 patients after 3 months and the remaining 13 patients were included in the long-term follow up. B cell populations were characterized by CD27/IgD/CD38/CD24 expression.

Results: One and three months following rituximab BM retained up to 30% of B cells while circulation was totally depleted of B cells. Analysis of the remaining BM B cells showed prevalence of immature and/or transitional B cells (CD38++CD24++) and CD27+IgD- memory cells, while IgD+ cells were completely depleted. A significant reduction of CD27+ cells in BM and in circulation was observed long after rituximab treatment (mean 22 months), while levels of naive B cells in BM and in circulation were increased. The levels of rheumatoid factor decline after rituximab treatment but returned to baseline levels at the time of retreatment.

Conclusions: Anti-CD20 treatment achieves a depletion of IgD+ B cells shortly after the treatment. At the long term follow up, a reduction of CD27+ B cells was observed in blood and BM. The prolonged inability to up-regulate CD27 may inhibit the renewal of memory B cells. This reduction of CD27+ B cells does not prevent autoantibody production suggesting that mechanisms regulating the formation of auto reactive clones are not disrupted by rituximab.

Figures

Figure 1
Figure 1
Short-term changes of the Ig-secreting cells in BM and PB after rituximab treatment. (a) Number of immunoglobulin (Ig)-secreting cells in bone marrow (BM) isolated from patients with rheumatoid arthritis at day 0, 1 and 3 months after rituximab treatment. Paired with respect to the sampling occasion. Error bars respresenting mean ± standard error of the mean. (b) Ig-secreting cells in peripheral blood (PB) at day 0, 3 and 6 months after rituximab treatment. Box represents 25th to 75th percentile, line indicates median, whereas error bars represent range. Statistical evaluation was performed using paired t-test.
Figure 2
Figure 2
Short- and long-term changes of RF levels in PB after rituximab treatment. (a) Rheumatoid factor (RF)-levels in peripheral blood (PB) at day 0, 3 and 6 months after rituximab treatment. (b) RF-levels in PB comparing rituximab-naïve and treated patients. Box represents 25th to 75th percentile, line indicates median, whereas error bars represent range. Statistical evaluation was performed using paired t-test (short-term changes) and Mann-Whitney t-test (long-term changes).
Figure 3
Figure 3
Short-term changes in the immunoglobulin expression of B cells following rituximab treatment. Isolated bone marrow mononuclear cells were stained for immunoglobulin (Ig) expression at day 0, 1 and 3 months after rituximab treatment. In (a) CD19+IgD+, (b) CD19+IgM+, (c) CD19+IgG+ and (d) CD19+IgA+ is shown. Box represents 25th to 75th percentile, line indicates median, whereas error bars represent range. Statistical evaluation was performed using paired t-test.
Figure 4
Figure 4
A representative plot of short-term and long-term changes of the B cell expression of CD27 and IgD on B cells in bone marrow from patients with rheumatoid arthritis receiving rituximab treatment. Lower left quadrant = immature B cells (IgD-CD27-); lower right quadrant = naïve B cells (IgD+CD27-); upper right quadrant = unswitched memory B cells (IgD+CD27+); and upper left quadrant = switched memory B cells (IgD-CD27+). (a) Rituximab-naïve patient is shown at day 0, 1 month and 3 months following treatment. (b) Rituximab-treated patient is shown at day 0, 1 month and 3 months following treatment. Arrow indicates depleted populations.
Figure 5
Figure 5
A representative plot of short-term and long-term changes of the B cell expression of CD38 in combination with CD10/CD24/IgD or CD27 in BM from RA patients receiving rituximab treatment. B cells expressing CD38 were analysed with respect to CD10/CD24, IgD or CD27 expression. Using CD38/IgD, plasmablast (CD38+++IgD-), immature and transitional B cells (CD38++IgD+/-), Bm5 (CD38+IgD-), Bm2 (CD38+IgD+) populations were defined. B cells from a rituximab-naïve patient at (a) day 0, (b) after 3 months, and (c) in a rituximab-treated patient at day 0, is shown for the combination of CD38/CD10/CD24/IgD/CD27.
Figure 6
Figure 6
Long-term changes in the immunoglobulin expression of B cells following rituximab treatment. Isolated bone marrow mononuclear cells were stained for immunoglobulin (Ig) expression comparing rituximab-naïve and treated patients. In (a) CD19+IgD+, (b) CD19+IgM+, (c) CD19+IgG+ and (d) CD19+IgA+ is shown. Box represents 25th to 75th percentile, line indicates median, whereas error bars represent range. Statistical evaluation was performed using the Mann-Whitney t-test.

References

    1. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710–4718.
    1. Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol. 2004;172:7694–7702.
    1. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999;42:1854–1860. doi: 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>;2-F.
    1. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43:2619–2633. doi: 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>;2-V.
    1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581. doi: 10.1056/NEJMoa032534.
    1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400. doi: 10.1002/art.21778.
    1. Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger JM, Kyburz D, Gabay C. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. Ann Rheum Dis. 2006;65:1255–1257. doi: 10.1136/ard.2005.051169.
    1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806. doi: 10.1002/art.22025.
    1. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146–2154. doi: 10.1002/art.11181.
    1. Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:476–483. doi: 10.1111/j.1365-3083.2007.01995.x.
    1. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1–Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol. 2001;167:3610–3618.
    1. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 2007;56:1464–1477. doi: 10.1002/art.22603.
    1. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105:4390–4398. doi: 10.1182/blood-2004-11-4284.
    1. Carlsson M, Nilsson K. Reactivity of Workshop B-cell antibodies with B-CLL cells induced to differentiate with or without concommitant proliferation. In: Knapp W, Dorken B, Gilkes WR, Rieber EP, Stein H, von dem Borne AEGKr, editor. leucocyte typing IV. Oxford University Press, Oxford; 1989. p. 206.
    1. de Rie MA, Terpstra FG, VanLier RAW, Borne KR Von Dern, Miedema F. Indentification of functional epitopes on Workshop-defined B-cell membrane molecules. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 402.
    1. Engel P, Ingles J, Gallart T, Vives J. Changes in the expression of B-cell surface antigen detected by the Workshop CD24 monoclonal antibodies following in vitro activation. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 206.
    1. Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol. 1990;144:638–641.
    1. Ling NR, MacLennan CM, Mason DY. B-cell and plasma cell antigens: new and previously defined clusters. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 302.
    1. Mittler RS, Talle MA, Carpenter K, Rao PE, Goldstein G. Generation and characterization of monoclonal antibodies reactive with human B lymphocytes. J Immunol. 1983;131:1754–1761.
    1. Pezzutto ABF, Callard RE, Clark EA, Genetet N, Goodahl AH, Gramatzki M, Hostoffer P, Cooper MD, Heldrup J, Campana D, Janossy G, Ling NR, Ledbetter JA, Ludwig WD, Pilkington GR, Steel CM, Tedder TF, Wijdenes J, Racadoet E, Dörken B. Flow Cytometry analysis of the B-cell blind panel: joint report. In: Knapp W, Dorken B, Gilkes WR, Rieber EP, Stein H, von dem Borne AEGKr, editor. leucocyte typing IV. Oxford University Press, Oxford; 1989. p. 165.
    1. Rabinovitch PS, Clark EA, Pezzutto A, Ledbetter JA, Draves KE. Modulation of human B-cell activation by Workshop monoclonal antibodies to B-cell associated differentiation antigens. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 435.
    1. Rawle FC, Armitage RJ, Iliescu V, Timms EM, Beverley PCL. Functional role of B-cell surface antigens. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 448.
    1. Shields JG, Smith SH, Callard RE. Modulation in responses to human B-cell growth and differentiation factors with monoclonal antibodies to B-cells surface antigens. In: McMichael AJ, Cobbold S, Crumpton MJ, Gilka W, Peter C. Beverly, editor. leucocyte typing III. Oxford University Press, Oxford; 1987. p. 448.
    1. Wang CY, Azzo W, Al-Katib A, Chiorazzi N, Knowles DM., 2nd Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes. J Immunol. 1984;133:684–691.
    1. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, Contentin N, Tilly H, Tron F, Vannier JP, Jacquot S. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol. 2008;127:14–25. doi: 10.1016/j.clim.2007.11.013.
    1. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–1669. doi: 10.1084/jem.20040119.
    1. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:772–778. doi: 10.1002/art.22400.
    1. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008;67:402–408. doi: 10.1136/ard.2007.074229.
    1. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122:139–145. doi: 10.1016/j.clim.2006.08.009.
    1. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377–2386. doi: 10.1002/art.22019.
    1. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007;46:29–36. doi: 10.1093/rheumatology/kel148.
    1. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman A, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2007
    1. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 2007;56:3909–3918. doi: 10.1002/art.22967.
    1. Avanzini MA, Locatelli F, Dos Santos C, Maccario R, Lenta E, Oliveri M, Giebel S, De Stefano P, Rossi F, Giorgiani G, Amendola G, Telli S, Marconi M. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol. 2005;33:480–486. doi: 10.1016/j.exphem.2005.01.005.
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HSTAM, Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324. doi: 10.1002/art.1780310302.
    1. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol. 1999;26:705–711.
    1. Amu S, Stromberg K, Bokarewa M, Tarkowski A, Brisslert M. CD25-expressing B-lymphocytes in rheumatic diseases. Scand J Immunol. 2007;65:182–191. doi: 10.1111/j.1365-3083.2006.01889.x.
    1. Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M. The Human Immunomodulatory CD25(+) B Cell Population belongs to the Memory B Cell Pool. Scand J Immunol. 2007;66:77–86. doi: 10.1111/j.1365-3083.2007.01946.x.
    1. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol. 2004;4:648–655. doi: 10.1038/nri1416.
    1. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58:1566–1575. doi: 10.1002/art.23473.
    1. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20:67–82. doi: 10.1016/j.smim.2007.12.006.
    1. Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B-cell subset profile diagnostic for Sjogren syndrome? Ann Rheum Dis. 2009;68:1447–1452. doi: 10.1136/ard.2008.096172.
    1. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med. 1994;180:329–339. doi: 10.1084/jem.180.1.329.
    1. Vugmeyster Y, Howell K, Bakshi A, Flores C, Hwang O, McKeever K. B-cell subsets in blood and lymphoid organs in Macaca fascicularis. Cytometry A. 2004;61:69–75. doi: 10.1002/cyto.a.20039.
    1. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983;65:109–121. doi: 10.1016/0022-1759(83)90308-3.
    1. Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC. Mature B cells class switched to IgD are autoreactive in healthy individuals. J Clin Invest. 2007;117:1558–1565. doi: 10.1172/JCI27628.
    1. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–826.
    1. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, Tedder TF. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;174:4389–4399.
    1. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467–496. doi: 10.1146/annurev.immunol.24.021605.090517.
    1. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19–28. doi: 10.1016/S0966-3274(03)00059-5.
    1. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W, Lowman H, McKeever K. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212–219. doi: 10.1097/01.cji.0000155050.03916.04.
    1. Lucio P, Parreira A, Beemd MW van den, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999;13:419–427. doi: 10.1038/sj/leu/2401279.
    1. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498–2507. doi: 10.1182/blood.V98.8.2498.
    1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
    1. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004;13:55–62.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir